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The systemic inflammatory response syndrome (SIRS) is a potentially lethal response 
triggered by diverse forms of tissue injury and infection. When systemic inflammation 
is triggered by infection, the term sepsis is used. Understanding how inflammation is 
mediated and regulated is of enormous medical importance. We previously demon-
strated that circulating inflammatory-relevant microRNAs (CIR-miRNAs) are candidate 
biomarkers for differentiating sepsis from SIRS. Here, we set out to determine how 
CIR-miRNA levels reflect SIRS severity and whether they derive from activated immune 
cells. Clinical disease severity scores and markers of red blood cell (RBC) damage or 
immune cell activation were correlated with CIR-miRNA levels in patients with SIRS and 
sepsis. The release of CIR-miRNAs modulated during SIRS was assessed in immune cell 
cultures. We show that severity of non-infective SIRS, but not sepsis is reflected in the 
levels of miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p. These CIR-miRNA 
levels positively correlate with levels of the redox biomarker, peroxiredoxin-1 (Prdx-1), 
which has previously been shown to be released by immune cells during inflammation. 
Furthermore, in  vitro activated immune cells produce SIRS-associated miR-378a-3p, 
miR-30a-5p, miR-30d-5p, and miR-192-5p. Our study furthers the understanding of the 
origin, role, and trafficking of CIR-miRNAs as potential regulators of inflammation.
Keywords: systemic inflammatory response syndrome, sepsis, microrna, inflammation, immune cells, sequential 
organ failure assessment score, mir-378, mir-30
inTrODUcTiOn
The systemic inflammatory response syndrome [SIRS (1)] can be triggered by diverse forms of injury 
including burns, ischemia, autoimmune diseases, injuries including surgery and infection. The sever-
ity of illness seen in SIRS varies widely but severe SIRS accompanied by multiple organ dysfunction 
syndrome (MODS), especially in the setting of sepsis (a condition which shares common clinical 
Abbreviations: miRNA, microRNA; CIR-miRNA, circulating inflammatory-relevant microRNA; SIRS, systemic inflammatory 
response syndrome; SOFA, sequential organ failure assessment; APACHE II, acute physiology and chronic health evaluation II; 
MODS, multiple organ dysfunction syndrome; CAR, compensatory anti-inflammatory responses; DAMPs, damage-associated 
molecular pattern molecules; PAMPs, pathogen-associated molecular pattern molecules; TLR, toll-like receptor; ROS, reactive 
oxygen species; TNF, tumor necrosis factor; TGF, tumor growth factor; CRP, C-reactive protein; sCD25, soluble CD25; Prdx-1, 
peroxiredoxin-1; Hb, hemoglobin; IL-, interleukin; PCT, pro-calcitonin; SAg, superantigen; SPE-K/L, streptococcal pyrogenic 
exotoxin K/L; PBMCs, peripheral blood mononuclear cells; RBCs, red blood cells; PBS, phosphate-buffered saline; FCS, fetal 
calf serum; RPMI, Roswell Park Memorial Institute medium; RT, reverse transcription/transcribed; IQR, interquartile ranges.
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manifestations with SIRS), may be lethal (2). Even with optimal 
medical care, mortality rates in severe sepsis increase to around 
50% (3). In this respect, clinical scores, such as the sequential 
organ failure assessment [SOFA (4)] and the acute physiology 
and chronic health evaluation II [APACHE II (5)], are useful to 
evaluate SIRS severity and patient mortality risk.
During SIRS, immune cell activation spreads to the whole 
body driving severe immunopathology (1, 6, 7). Damage- and/or 
pathogen-associated molecular pattern molecules (respectively, 
DAMPs and PAMPs) released after injury (or infection) initiate, 
via toll-like receptor (TLR) signals (6, 8), an activation cascade in 
immune and endothelial cells leading to inflammatory cytokine 
production [e.g., tumor necrosis factor (TNF) α, IL-1, IL-6, and 
IL-8], in a so-called “cytokine storm” (9, 10). Activated inflam-
matory cells migrate to affected organs and release secondary 
inflammatory mediators (1), including reactive oxygen species 
(ROS) and nitrogen species (11–15), resulting in oxidative stress 
(16, 17). Inflammatory cell migration to tissues and endothelial 
cell activation (18) lead to disseminated intravascular coagulation 
(19) aggravating organ damage. Increased levels of TNFα, IL-1, 
and IL-6 have been reported to occur more often in sepsis than 
SIRS (1, 20–22). Anti-inflammatory mediators (e.g., TGFβ and 
cytokine antagonists) are also present in plasma during SIRS, 
with soluble cytokine receptors often found at concentration 
higher than the respective cytokines (20, 23), hence compensa-
tory anti-inflammatory responses [CAR (24)] may be activated 
during SIRS. Understanding the responses which occur in non-
infective inflammation and sepsis and how they are regulated will 
aid development of diagnostics and therapeutics in these major 
inflammatory diseases.
MicroRNAs (miRNAs) are small (~23 nt) RNAs that function 
as post-transcriptional gene regulators (25, 26). By annealing to 
complementary sequences in the 3′ untranslated region (3′ UTR) 
of target mRNAs, they reduce expression of specific proteins by 
promoting target degradation or inhibition of translation (26). 
The role of miRNAs in SIRS remains unclear, although many 
inflammatory cytokines, mediators, and their regulators are 
miRNA targets (27). Approximately 100–200 miRNAs are found 
in human blood in health and disease (28–30). Previous studies 
(31, 32) suggest that exogenous miRNAs may be detected by TLRs 
(33, 34), particularly TLR7 (32), as potential DAMPs leading to 
inflammatory signals. We previously identified a pool of circulat-
ing inflammatory-relevant miRNA (CIR-miRNAs) that robustly 
distinguish sepsis from non-infective SIRS (35). We were the first 
to find that, in these conditions, CIR-miRNA levels inversely cor-
relate with those of inflammatory cytokines (35), suggesting that 
they may be part of the CAR.
To extend these observations, we set out to determine how 
CIR-miRNAs reflect SIRS severity and whether they are likely 
to arise directly from immune activation. In this study, we 
investigated the correlation of plasma levels of CIR-miRNAs 
with disease severity and other inflammatory parameters. We 
found that SIRS severity significantly impacts on the levels of 
miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p. These 
CIR-miRNAs are unlikely to derive from red blood cell (RBC) 
damage consequent to hemolysis or coagulopathy. Instead their 
levels positively correlate with levels of the redox biomarker, 
Prdx-1, which is released by immune cells during inflammation 
(36, 37). Finally, we show that activated immune cells produce 
SIRS-associated miR-378a-3p, miR-30a-5p, miR-30d-5p, and 
miR-192-5p, in  vitro. Our study has implications for further-
ing the understanding of the origin and role and trafficking of 
CIR-miRNAs in SIRS, sepsis, and potentially other inflammatory 
disease.
MaTerials anD MeThODs
Patients and healthy Donors
The patient population used in this study was previously 
described in detail (35, 38). Briefly, patients comprised unse-
lected adult admissions to a mixed medical/surgical intensive/
high-dependency care unit (ICU/HDU) at an English acute 
hospital (Brighton and Sussex University Hospitals NHS Trust). 
Patients were categorized as having non-infective SIRS (n = 44) 
or sepsis (n = 29), following standard criteria (38). SIRS severity 
was defined as: severe (SOFA ≥ 6) and non-severe (SOFA ≤ 3); 
patients with intermediate SOFA scores of 4–5 were excluded. 
Only patients with abdominal sepsis were included in this study. 
Blood samples were collected within <6 h from admission and 
time of sample collection did not affect levels of CIR-miRNAs 
(35). Healthy donors were recruited at Brighton and Sussex 
Medical School (BSMS, University of Sussex, Falmer, Brighton, 
UK). Refer to Materials and Methods in Supplementary Material 
for further details, including details of any medication targeting 
inflammation that patients were taking at the time of admission.
hemoglobin, Prdx-1, and cytokine 
analysis in Plasma samples
Red blood cell lysis can bias miRNA content in plasma (39, 40). 
The concentration of free hemoglobin (Hb) was independently 
measured in patient plasma by the Harboe spectrophotometric 
method (41, 42) and hemolytic samples (43–45) were excluded, 
as carried out previously (35). Prdx-1 plasma levels were 
independently measured using an ELISA kit for human Prdx-1 
(#ABIN418422) from Antibodies Online (Aachen, Germany). 
Plasma cytokines (IL-6, IL-8) and anti-/inflammatory mediators 
[pro-calcitonin (PCT), C-reactive protein (CRP), and soluble 
CD25 (sCD25)] were measured on Luminex LX200 and ELISA 
(sCD25) as previously described (38).
human samples and Primary cell cultures
Human peripheral blood mononuclear cells (PBMCs) from 
healthy donors were freshly isolated by centrifugation over 
Ficoll–Hypaque density gradient as previously described (46). 
Cells were washed in sterile PBS (ThermoFisherScientific) and 
counted with 0.1% Trypan Blue cell viability exclusion dye (Sigma). 
Thereafter, 20 ×  106 viable PBMCs were resuspended in 10  ml 
(2 × 106 cells/ml) of complete media: RPMI containing 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 2 mM l-glutamine (all from 
ThermoFisherScientific) and 10% of exosome-depleted, heat-
deactivated fetal calf serum (System Biosciences). PBMCs were 
stimulated with the bacterial superantigen (SAg), streptococcal 
pyrogenic exotoxin K/L [SPE-K/L (47)] as described before (46), 
TaBle 1 | Correlations of circulating inflammatory-relevant microRNAs (CIR-
miRNAs) with severity of systemic inflammatory response syndrome (SIRS) as 
detected by sequential organ failure assessment (SOFA).
Microrna 
speciesa
sOFa 
spearman 
correlation (ρ)b
correlation 
significance 
pc
Benjamini–
hochberg 
(Bh) rank
Bh critical 
value  
(FDr 15%)
mir-378a-3p 0.491 0.00084 1* 0.00349
mir-30a-5p 0.433 0.00370 2* 0.00698
mir-30d-5p 0.412 0.00609 3* 0.01047
mir-192-5p 0.378 0.01253 4* 0.01395
mir-122-5p 0.359 0.01799 5 0.01744
mir-101-3p 0.351 0.02092 6 0.02093
mir-21-5p 0.336 0.02769 7 0.02442
mir-148a-3p 0.309 0.04357 8 0.02791
miR-10b-5p 0.283 0.06601 9 0.03140
miR-532-5p 0.285 0.07054 10 0.03488
mir-22-3p 0.268 0.08248 11 0.03837
miR-143-3p 0.266 0.08468 12 0.04186
miR-23a-3p 0.255 0.09926 13 0.04535
miR-320a 0.251 0.10514 14 0.04884
miR-486-5p −0.251 0.10514 15 0.05233
The top 15 performing miRNAs are shown. Significant correlations with disease severity 
are highlighted in bold black (SIRS) or red (sepsis). Refer to Table S4 in Supplementary 
Material for the full dataset.
aGreen-shadowed cells indicate miRNAs that passed the BH correction for multiple 
comparisons.
bBlue- and violet-shadowed cells indicate miRNAs that returned positive and negative 
correlations (ρ ≥ 0.2 or ρ ≤ −0.2), respectively.
cBrown- and red-shadowed cells indicate miRNAs that returned significant correlations 
(p ≤ 0.05) and additionally passed the correction for multiple comparisons, respectively.
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in parallel to unstimulated control cultures (24-well plates, 1 ml/
well). After 5 days, cells were harvested and assayed for viability 
with Trypan-blue (0.1%) (Figure S7 in Supplementary Material). 
Equal volumes of culture supernatants were then recovered, 
frozen at −80°C and total RNA was then extracted as described 
below.
rna extraction and Microrna  
real-Time qPcr array
Plasma and supernatant RNA was extracted using the miR-
CURY™ RNA isolation—biofluids kit (Exiqon, Denmark). After 
thawing on ice, an RNA spike-in template mixture was added 
to the samples. Eight milliliters of supernatant per sample was 
mixed with 2.4 ml of Lysis solution BF containing 16.67 µg/ml of 
MS2 bacteriophage RNA (UniSp6), prior to RNA purification, as 
specified by the manufacturer’s instructions. Extracted total RNA 
was stored in a −80°C freezer. RNA was reverse transcribed (RT) 
and cDNA analyzed using the miRCURY LNA™ Universal RT 
miRNA PCR, Polyadenylation, and cDNA synthesis method. For 
plasma samples derived from patients (≥8 biological replicates), 
each microRNA was assayed by qPCR (miRNA Ready-to-Use 
PCR, Pick-&-Mix using ExiLENT SYBR® Green master mix) in 
two independent technical repeats, including negative controls 
(no-template from the RT reaction) using a LightCycler® 480 
Real-Time PCR System (Roche). SAg stimulation experiments 
were performed as 10 independent biological replicates. Assays 
returning three crossing point (Cp) values less than the negative 
control and Cp < 37 were accepted. The stability values of candi-
date normalizers were assessed using the “NormFinder” software 
(48). Any qPCR data were normalized to the average Cp of internal 
normalizers [miR-320a and miR-486-5p (35)] in plasma samples 
and, in the case of culture supernatants, the Cp of normalizer 
spike-in (UniSp6); (delta Cp, dCp = normalizer Cp − assay Cp). 
Refer to the Materials and Methods in the Supplementary Material 
for further details.
statistical analyses
Datasets were analyzed using the GraphPad Prism 6 and/or 
IBM SPSS Statistics 22 software. The D’Agostino and Pearson 
omnibus and Shapiro–Wilk tests were used to test normal data 
distribution; data were considered normally distributed only 
if they passed both tests. If not normally distributed, medians 
with interquartile ranges (IQRs, rather than means and SD) 
are shown and Mann–Whitney U Test (rather than t-tests) was 
used to calculate p values in 2-group comparisons. Correlations 
between SOFA and APACHE II scores and plasma levels of 
CIR-miRNAs and inflammatory cytokines/mediators were 
evaluated using the Spearman rho (ρ) and significances of the 
correlations determined as indicated. Generally, 0.35 ≤ ρ ≤  1 
or −1  ≤  ρ  ≤  −0.35 were considered as moderate-to-strong 
correlation trends (49, 50). The confidence in the predictive 
value of each correlation was assessed by individual p values; in 
general, correlations trends were considered significant only if 
p ≤ 0.05 (51). In addition, for the qPCR miRNA array dataset, 
a Benjamini–Hochberg multiple comparison correction (52) 
was used to control for the number of false positives, using 
false discovery rates of 15% (Tables 1 and 2; Tables S1 and S2 in 
Supplementary Material) and 5% (Tables 3 and 4) which cor-
respond to a ~1/6 and 1/20 chance of false positives, respectively. 
Such correction excludes that the significance of correlation of 
any parameter (such as disease severity, free Hb and Prdx-1) 
with any of the 43 miRNA tests run in parallel was not simply 
due to the chance of multiple testing. Unless stated differently in 
figure legends, levels of significance were assigned as: *p ≤ 0.05; 
**p ≤ 0.005; and ***p ≤ 0.0005. MiRNA and cytokine, Hb, and 
Prdx-1 analyses were conducted blind to the clinical data.
resUlTs
severity of non-infective sirs Positively 
correlates with the levels of cir-mirnas
To determine whether CIR-miRNA levels are regulated by the 
severity of SIRS, Cp of single miRNAs were compared to the 
mean Cp of internal normalizers [as previously identified (35)] 
to give dCp values that increase with the abundancy of specific 
miRNAs. Severity of disease, according to the SOFA score, was 
then correlated with dCp in non-infective SIRS patients. Thirteen 
CIR-miRNAs showed generally positive trends correlating with 
SIRS severity (Table 1). Significantly, 8 miRNAs showed a posi-
tive correlation with the disease severity (Table 1, black bold), 
with miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p 
further passing the Benjamini–Hochberg correction for multiple 
comparisons (52) (Figure 1A). We further determined whether 
CIR-miRNA levels correlate with disease severity in sepsis 
patients (Figure 1B). None of the CIR-miRNAs correlating with 
TaBle 4 | Correlations of circulating inflammatory-relevant microRNAs (CIR-
miRNAs) with peroxiredoxin-1 levels in non-infective systemic inflammatory 
response syndrome (SIRS).
Microrna 
speciesa
Prdx1 
spearman 
correlation (ρ)b
correlation 
significance pc
Benjamini 
hochberg
(Bh) rank
Bh critical 
value  
(FDr 5%)
mir-192-5p 0.590909 3.02E-05 1 0.00116
mir-30a-5p 0.548626 1.39E-04 2 0.00233
mir-22-3p 0.536243 2.10E-04 3 0.00349
mir-122-5p 0.505436 0.000545917 4 0.00465
mir-148a-3p 0.485956 0.00095437 5 0.00581
mir-378a-3p 0.485503 0.000966472 6 0.00698
miR-532-5p 0.465157 0.002181351 7 0.00814
miR-320a 0.453186 0.002274844 8 0.00930
miR-486-5p −0.45319 0.002274844 9 0.01047
mir-21-5p 0.437632 0.003337895 10 0.01163
mir-101-3p 0.413168 0.005892309 11 0.01279
miR-423-5p 0.340985 0.02524517 12 0.01395
mir-30d-5p 0.318571 0.03733837 13 0.01512
mir-375 0.342017 0.04432343 14 0.01628
miR-10b-5p 0.266687 0.08386032 15 0.01744
The top 15 performing miRNAs are shown. miRNAs significantly correlating with 
disease severity (as by sequential organ failure assessment) are highlighted in bold 
black (SIRS) or red (sepsis). Refer to Table S7 in Supplementary Material for the full 
dataset.
aGreen-shadowed cells indicate miRNAs that passed the BH correction for multiple 
comparisons.
bBlue- and violet-shadowed cells indicate miRNAs that returned positive and negative 
correlations (ρ ≥ 0.2 or ρ ≤ −0.2), respectively.
cBrown- and red-shadowed cells indicate miRNAs that returned significant correlations 
(p ≤ 0.05) and additionally passed the correction for multiple comparisons, respectively.
TaBle 3 | Correlations of circulating inflammatory-relevant microRNAs (CIR-
miRNAs) with free hemoglobin levels in non-infective systemic inflammatory 
response syndrome (SIRS).
Microrna
speciesa
hb spearman 
correlation (ρ)b
correlation 
significance pc
Benjamini 
hochberg
(Bh) rank
Bh critical 
value  
(FDr 5%)
mir-21-5p −0.6308 5.78E-06 1 0.00116
miR-10b-5p −0.5297693 2.59E-04 2 0.00233
miR-320a −0.5080983 0.000504483 3 0.00349
miR-486-5p 0.5080983 0.000504483 4 0.00465
mir-375 −0.5562014 0.000521672 5 0.00581
miR-451a 0.5024351 0.000596273 6 0.00698
miR-30e-3p −0.4792892 0.001521716 7 0.00814
mir-30a-5p −0.4631706 0.001761638 8 0.00930
miR-92b-3p −0.4986164 0.001966918 9 0.01047
mir-22-3p −0.4430098 0.002929346 10 0.01163
mir-122-5p −0.4416506 0.00302822 11 0.01279
miR-28-3p −0.4402159 0.003135754 12 0.01395
miR-146a-5p −0.4328161 0.00374532 13 0.01512
mir-192-5p −0.4219428 0.004828522 14 0.01628
mir-101-3p −0.4151471 0.005636129 15 0.01744
The top 15 performing miRNAs are shown. miRNAs significantly correlating with 
disease severity (as by sequential organ failure assessment) are highlighted in bold 
black (SIRS) or red (sepsis). Refer to Table S6 in Supplementary Material for the full 
dataset.
aGreen-shadowed cells indicate miRNAs that passed the BH correction for multiple 
comparisons.
bBlue- and violet-shadowed cells indicate miRNAs that returned positive and negative 
correlations (ρ ≥ 0.2 or ρ ≤ −0.2), respectively.
cBrown- and red-shadowed cells indicate miRNAs that returned significant correlations 
(p ≤ 0.05) and additionally passed the correction for multiple comparisons, respectively.
TaBle 2 | Correlations of circulating inflammatory-relevant microRNAs 
(CIR-miRNAs) with severity of sepsis as detected by sequential organ failure 
assessment (SOFA).
Microrna 
speciesa
sOFa 
spearman 
correlation (ρ)b
correlation 
significance 
pc
Benjamini–
hochberg
(Bh) rank
Bh critical 
value  
(FDr 15%)
mir-22-3p 0.447 0.01942 1 0.00349
mir-191-5p −0.432 0.02436 2 0.00698
mir-375 0.590 0.02633 3 0.01047
miR-151a-3p −0.354 0.06990 4 0.01395
miR-146a-5p −0.333 0.08966 5 0.01744
miR-103a-3p −0.299 0.12992 6 0.02093
mir-378a-3p 0.282 0.16305 7 0.02442
let7b-5p −0.269 0.17521 8 0.02791
mir-122-5p 0.262 0.19539 9 0.03140
let7i-5p −0.252 0.20556 10 0.03488
mir-192-5p 0.228 0.25220 11 0.03837
miR-23a-3p −0.224 0.26149 12 0.04186
miR-92b-3p −0.304 0.27048 13 0.04535
miR-10a-5p −0.275 0.28483 14 0.04884
miR-28-3p −0.192 0.34735 15 0.05233
The top 15 performing miRNAs are shown. Significant correlations with disease severity 
are highlighted in bold black (SIRS) or red (sepsis). Refer to Table S5 in Supplementary 
Material for the full dataset.
aGreen-shadowed cells indicate miRNAs that passed the BH correction for multiple 
comparisons.
bBlue- and violet-shadowed cells indicate miRNAs that returned positive and negative 
correlations (ρ ≥ 0.2 or ρ ≤ −0.2), respectively.
cBrown- and red-shadowed cells indicate miRNAs that returned significant 
correlations (p ≤ 0.05) and additionally passed the correction for multiple 
comparisons, respectively.
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disease severity in SIRS showed similar significant trends in 
sepsis (Figure 1B; Table 2). Although miR-22-3p, miR-375, miR-
122-5p, miR-192-5p, and miR-378a-3p maintained modestly 
positive non-significant trends, multiple CIR-miRNAs showed 
generally inverse trends with sepsis severity (Table 2).
In comparison to pro-inflammatory cytokines (IL-8 and 
IL-6) and soluble mediators of inflammation and stress such 
as CRP, PCT, free hemoglobin (Hb), and Prdx-1, CIR-miRNAs 
showed more robust correlations with disease severity (compare 
Figures  1A and 2A). None of these inflammatory mediators 
showed a significant correlation with SIRS severity, although 
some non-significant trends were apparent (Figure 2A). While 
levels IL-8, IL-6, CRP, and PCT increased in sepsis compared to 
non-infective SIRS, only IL-6 positively correlated with sepsis 
severity (Figure 2B).
Similar analyses were performed using the APACHE II in 
alternative to the SOFA severity score. In agreement with our 
previous analysis, CIR-miRNA levels positively and significantly 
correlated with the APACHE II score in non-infective SIRS 
(Figure S1A and Table S1 in Supplementary Material), but not 
in sepsis (Figure S1B and Table S2 in Supplementary Material). 
In addition, CIR-miRNAs in comparison to IL-6, CRP, PCT, and 
free Hb, generally showed more robust correlations with the 
APACHE II score, while IL-8 and Prdx-1 had significant posi-
tive correlation with the APACHE II score in non-infective SIRS 
(Figure S2A in Supplementary Material), but not in sepsis (Figure 
S2B in Supplementary Material).
FigUre 1 | Circulating inflammatory-relevant microRNA levels correlate with the severity of non-infective systemic inflammatory response syndrome (SIRS). In 
miRNA qPCR arrays, within each patient’s specimen, crossing point (Cp) of a single miRNA is compared to the mean Cp of 2 normalizers (miR-486-5p and 
miR-320a) to give delta Cp (dCp). dCp of non-infective SIRS (a) and sepsis (B) patients were analyzed in correlation analyses with disease severity, as determined 
by the sequential organ failure assessment (SOFA) score. (a) Non-parametric correlation of SOFA scores with the plasma levels of miR-378a-3p, miR-30a-5p, 
miR-30d-5p, and miR-192-5p in non-infective SIRS patients (n = 43 for all miRNAs). (B) Non-parametric correlation of SOFA scores with the plasma levels of 
miR-378a-3p (n = 26), miR-30a-5p (n = 24), miR-30d-5p (n = 27), and miR-192-5p (n = 27) in infective SIRS (sepsis) patients. Each symbol represents an individual 
patient. Correlation trends are shown with the linear regression model including Spearman rho (ρ) and the significances of the correlations (*p ≤ 0.05; **p ≤ 0.005; 
and ***p ≤ 0.0005 or ns, non-significant).
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FigUre 2 | Correlations of plasma levels of inflammatory cytokines and stress mediators with the severity of non-infective systemic inflammatory response 
syndrome and sepsis. The levels of inflammatory cytokines (interleukin-IL-8 and IL-6) and stress mediators: C-reactive protein (CRP), pro-calcitonin (PCT), 
free hemoglobin (Hb), and peroxiredoxin-1 (Prdx-1) were measured by ELISA in the plasma of non-infective SIRS (a) and sepsis (B) patients. Thereafter, 
the correlation with the severity of disease, as determined by the sequential organ failure assessment (SOFA) score was investigated. (a) Non-parametric 
correlation of SOFA scores with the plasma levels of IL-8 (n = 43), IL-6 (n = 43), CRP (n = 43), PCT (n = 42), free Hb (n = 43), and Prdx-1 (n = 41) in 
non-infective SIRS patients. (B) Non-parametric correlation of SOFA scores with the plasma levels of IL-8 (n = 26), IL-6 (n = 27), CRP (n = 27), PCT 
(n = 27), free Hb (n = 27), and Prdx-1 (n = 24) in sepsis patients. Each triangle represents an individual patient. Correlation trends are shown with the 
linear regression model, including Spearman rho (ρ) and the significances of the correlations (* p ≤ 0.05; **p ≤ 0.005; and ***p ≤ 0.0005 or ns, non-
significant).
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cir-mirnas significantly Discriminate 
severe from non-severe sirs
Consistent with a steady accumulation of CIR-miRNAs in 
more severe disease, dCp values were higher in severe rather 
than non-severe SIRS (Figure  3A) for the most significantly 
affected CIR-miRNAs. Hence, miR-378a-3p, miR-30a-5p, miR-
30d-5p, and miR-192-5p distinguished non-severe from severe 
SIRS patients (Figure  3A). Also miR-122-5p, miR-101-3p, 
miR-21-5p, miR-148a-3p, and miR-532-5p (which all had 
non-significant positive trends to increase with SIRS severity, 
Table  1) significantly discriminated severe from non-severe 
SIRS (Figure S3 in Supplementary Material). By contrast, none 
of the inflammatory cytokines and stress mediators we meas-
ured in our cohort discriminated SIRS severity groups, includ-
ing IL-8 (Figure 3B) and IL-6 (Figure S3B in Supplementary 
Material).
sirs-relevant cir-mirnas are Unlikely 
to Derive from rBcs
We next investigated where the CIR-miRNAs regulated by SIRS 
severity may originate. We reasoned that if they derived from 
RBCs that contain multiple miRNAs (released in the blood after 
physiological hemolysis or coagulopathy), then CIR-miRNA 
levels would positively correlate with the amount of free Hb. 
Instead, around 95% of the analyzed CIR-miRNAs (40/43) 
showed inverse correlation trends with free Hb (Tables 3; Table 
S6 in Supplementary Material). Many CIR-miRNAs, includ-
ing miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p 
(Figure  4A) and miR-101-3p, miR-21-5p, miR-22-3p, miR-
423-5p, and miR-122-5p (Figure S4 in Supplementary Material) 
significantly inversely correlated with free Hb levels even after a 
stringent Benjamini–Hochberg correction (52), supporting that 
CIR-miRNAs relevant in severe SIRS do not derive from RBCs. 
By contrast, free Hb levels positively correlated with miRNAs 
abundant in RBCs (29), miR-486-5p and miR-451a (Figure 4B; 
Table 3), consistent with a RBC origin.
cir-mirnas Positively correlate with 
redox Biomarker Prdx-1
We sought to investigate whether SIRS-relevant CIR-miRNAs 
derive from immune cells (i.e., white blood cells). To do this, 
we used Prdx-1, a marker that we had previously found to be 
released by immune cells after inflammatory stimuli (36, 37). 
Consistently, in the entire SIRS cohort, Prdx-1 levels correlated 
with markers of immune activation (IL-8 and sCD25), rather 
than free Hb (Figure S5 in Supplementary Material), demon-
strating that Prdx-1 did not increase due to RBC hemolysis. 
We then analyzed the correlation of Prdx-1 with CIR-miRNA 
dCp (Figure 5; Table 4). Around 40% (18/43) of CIR-miRNAs 
showed moderate-to-strong correlation trends with Prdx-1 lev-
els, with a prevalence of positive relationships (Tables 4; Table S7 
in Supplementary Material). Levels of 10 CIR-miRNAs, includ-
ing miR-378a-3p, miR-30a-5p, and miR-192-5p (Figure  5A) 
and miR-101-3p, miR-21-5p, miR-22-3p, and miR-122-5p 
(Figure S6 in Supplementary Material) significantly positively 
correlated with those of Prdx-1, suggesting that the amounts of 
CIR-miRNAs modulated in non-infective SIRS mirror those of 
this inflammatory biomarker. By contrast, miRNAs abundant 
in RBCs, miR-486-5p (Figure  5B) and miR-451a (Table S7 in 
Supplementary Material), did not show positive correlation with 
Prdx-1.
stimulated immune cells Produce  
cir-mirnas affected by severity of sirs
To determine whether immune cells could produce miR-
378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p, PBMCs of 
10 healthy donors were stimulated in vitro with bacterial SAg, 
known to drive massive inflammatory cell activation. After 
5  days, viability of the cell cultures was determined using the 
Trypan-blue dye exclusion assay (Figure S7 in Supplementary 
Material). Relative to a normalizer spike-in, we found increased 
amounts of miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-
192-5p in culture supernatants of stimulated PBMCs compared 
to unstimulated controls (Figure 6A). The increase of miRNAs 
in the supernatants varied across the miRNA species between 
10- and 100-fold (Figure 6B), with the notable exception of miR-
122-5p that was not significantly increased (Figures 6A,B). In 
cultures derived from four donors, levels of miR-10b-5p, which 
did not discriminate non-severe from severe SIRS (Figure S3 
in Supplementary Material), did not increase upon activation 
(Figures 6A,B).
DiscUssiOn
We report here that, during non-infective SIRS, the blood levels 
of CIR-miRNAs increase in parallel with the severity of inflam-
mation. Levels of CIR-miRNAs do not correlate with those of 
free Hb, indicating that they do not derive from RBCs during 
SIRS. Instead, CIR-miRNAs positively correlate with levels of 
the inflammatory mediator and redox enzyme, Prdx-1 which 
is released by immune cells in inflammation. Consistently 
miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p 
affected by severity of SIRS are produced by immune cells 
upon activation. As CIR-miRNAs are increasingly proposed as 
biomarkers for sepsis, cancer, and other disease (35, 53–55), 
their inflammatory cell origin should be considered in future 
research.
In our study, CIR-miRNAs distinguish non-severe from 
severe SIRS better than inflammatory cytokines and mediators. 
Inflammatory cytokines are thought to be released during SIRS 
as part of the cytokine storm, during MODS (1). As in our cur-
rent study, plasma levels of cytokines have not previously been 
found to reliably increase in severe SIRS (1), perhaps due to low 
cytokine concentration and short half-life in samples (56, 57). 
By contrast, regulators of inflammatory mediators are abundant 
in the blood of SIRS patients (20), as we found to be the case 
for the CIR-miRNAs affected by SIRS severity (Figure 3; Figure 
S3 in Supplementary Material). In addition, it should be noted 
that blood levels of miR-378a-3p, miR-30a-5p, miR-30d-5p, and 
miR-192-5p were regulated by disease severity, irrespectively 
FigUre 3 | Circulating inflammatory-relevant microRNA biomarkers discriminate the severity of systemic inflammatory response syndrome (SIRS) better than 
inflammatory and stress mediators. In miRNA qPCR arrays, within each patient’s specimen, crossing point (Cp) of individual miRNAs were normalized as in Figure 1 
and analyzed in patients with non-severe (open circles) and severe (filled circles) non-infective SIRS. Each symbol represents an individual patient. (a) Dot plots show 
delta Cp values for miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p in non-severe (n = 21) and severe (n = 22) non-infective SIRS patients, together with 
the level of significance. (B) Dot plots show concentration of IL-8, pro-calcitonin (PCT), peroxiredoxin-1 (Prdx-1) and free hemoglobin (Hb) in non-severe (n = 21) and 
severe (n = 22, apart from Prdx-1 in which n = 20) non-infectious SIRS patients, together with the level of significance.
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FigUre 4 | Circulating inflammatory-relevant microRNA levels inversely correlate with markers of red-blood cell lysis. In miRNA qPCR arrays, within each patient’s 
specimen, crossing point (Cp) of individual miRNAs (open squares) were normalized as in Figure 1 and analyzed in correlation with levels of free Hb, which is 
derived from the lysis of red blood cells. Each square represents an individual patient. Correlation trends are shown with the linear regression model including 
Spearman rho (ρ) and the significances of the correlations (*p ≤ 0.05; **p ≤ 0.005; and ***p ≤ 0.0005 or ns, non-significant) for (a) miR-378a-3p, miR-30a-5p, 
miR-30d-5p, and miR-192-5p and (B) miR-486-5p in non-infective systemic inflammatory response syndrome patients (n = 43).
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from whether patients were taking anti-inflammatory drugs (at 
the time of admission) (Figure S8 and Table S8 in Supplementary 
Material).
CIR-miRNAs may act as regulators of inflammation (35) by 
targeting the 3′UTR of mRNAs encoding pro-inflammatory 
cytokines/mediators (58–61). Many miRNAs are involved in 
inflammation/immune function (27), including miR-378 (62, 63), 
miR-30a/d (64, 65), miR-192 (64–68), and others found in this 
study (69). Interestingly, the more severe SIRS is, the more CIR-
miRNAs are released, potentially counteracting systemic inflam-
mation as part of the CAR (24). Significantly, direct or indirect 
targets of miR-378, miR-30a/d, and miR-192 include, among 
FigUre 5 | Circulating inflammatory-relevant microRNA levels positively correlate with markers of immunological stress, peroxiredoxin-1 (Prdx1). In miRNA qPCR 
arrays, within each patient’s specimen, crossing point (Cp) of individual microRNAs (miRNAs) (open rhombi) were normalized as in Figure 1 and analyzed in 
correlation with levels of plasma inflammatory stress marker, Prdx-1. Each symbol represents an individual patient. Correlation trends are shown with the linear 
regression model including Spearman rho (ρ) and the significances of the correlations (*p ≤ 0.05; **p ≤ 0.005; and ***p ≤ 0.0005 or ns, non-significant) for (a) 
miR-378a-3p, miR-30a-5p, miR-30d-5p, and miR-192-5p, and (B) miR-486-5p in non-infective systemic inflammatory response syndrome patients (n = 41).
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other genes, IL-1A (70), IL-1R (71), IL-17 (72), IL-17RA, and 
IL-17RE (73). In contrast, CIR-miRNA levels did not correlate 
with sepsis severity (compare Tables 1 and 2; Tables S1 and S2 in 
Supplementary Material), suggesting that inflammatory pathways 
leading to CIR-miRNA accumulation in blood are dysregulated 
in sepsis. Consequently, upon sepsis progression, the negative 
regulation exerted by CIR-miRNAs may be restrained, thus 
boosting immunopathology. Inflammatory cytokine (IL-1, IL-6, 
etc.) levels increased consistently much more in sepsis than in 
SIRS (35), therefore inflammatory mRNAs may act as a “sponge” 
to sequestrate miRNAs in sepsis, but not in other trauma includ-
ing SIRS (74). Although miR-30a was recently associated with 
FigUre 6 | Levels of circulating inflammatory-relevant microRNAs affected 
by the severity of systemic inflammatory response syndrome (SIRS) are 
increased in supernatants of blood-derived immune cell cultures. PBMCs 
derived from 10 individuals were freshly purified from blood and equal cell 
numbers were then incubated in complete media in the presence of 
exosome-free bovine serum, strictly at the concentration of 2 × 106 cells/ml, 
in replicate wells. Half of the cultures were stimulated with the SPE-KL 
bacterial superantigen (SAg) from 5 days, in comparison to unstimulated 
controls (unstim). On day 5, cells were harvested and equal volumes of 
supernatants were recovered after two sequential spins prior to RNA 
extraction as detailed in the Section “Materials and Methods.” The presence 
of microRNAs regulated (miR-378a-3p, miR-30a-5p, miR-30d-5p, 
miR-192-5p, and miR-122-5p) or unaffected (miR-10b-5p) by the severity of 
non-infective SIRS was assessed in Q-PCR array in multiple biological 
replicates. (a) Within each donor’s specimen, crossing point (Cp) of a single 
miRNA is compared to the Cp of a spike-in RNA added to supernatants just 
prior to the RNA-purification to give delta Cp (dCp). dCp were then linearized 
to give the relative expression of individual miRNAs in supernatants from 
unstimulated (black bars; n = 10, 7, 5, 7, 10, 4, respectively, for miR-378a-
3p, miR-30a-5p, miR-30d-5p, miR-192-5p, miR-122-5p, and miR-10b-5p) 
compared to SAg-activated cells (gray bars; n = 10, 10, 8, 9, 10, and 9, 
respectively, for miR-378a-3p, miR-30a-5p, miR-30d-5p, miR-192-5p, 
miR-122-5p, and miR-10b-5p). (B) Average miRNA fold-induction in 4–10 
individuals were calculated as the average ratio of miRNA levels detected in 
supernatants from SAg-activated cells compared to unstimulated cultures.
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induction of myeloid derived suppressor cells in cancer (75), the 
question of whether CIR-miRNAs are anti-inflammatory and 
ameliorate sepsis outcome remains to be further investigated.
Alternatively, CIR-miRNAs may act as modulators of 
inflammation via indirect effects (i.e., by not targeting directly 
inflammatory cytokine expression). For instance, at least in mice, 
miR-378 is known to target phosphoinositide 3 kinase (PI3K) 
expression in liver cells, affecting liver metabolism with systemic 
effects which may be relevant during systemic inflammatory 
disease and MODS (76). Furthermore, PI3K pathway is also cru-
cially regulated during immune cell proliferation, differentiation, 
and apoptosis (77), all of which may affect immune cell func-
tion during SIRS. Similarly, miR-30a has been shown to target 
the expression of Blimp-1 (78) (an important differentiation 
factor in immune cells) and various members of the calcineurin 
signaling pathway, including NFATc3 (79) at least in podocytes 
and cardiomyocytes, which might have implications for MODS 
and inflammation. Finally, miR-192 has been shown to suppress 
cell-proliferation pathways in myeloma (80) and other leukemic 
cells (81). However for all abovementioned cases, whether the 
same targets are also regulated in normal immune cells remains 
so far elusive.
Altogether, our results have implications for clinical practice 
and future therapeutic interventions. In particular in ICU/HDU, 
using miRNAs to distinguish non-infective SIRS from sepsis and 
severe from non-severe SIRS could help guide patient manage-
ment, for example, triaging patients based on severity, informing 
decisions based on prognosis, and helping target therapy includ-
ing the need for and choice of antibiotics. In future, miRNAs 
may become markers and/or targets for novel immunotherapy 
for acute inflammatory conditions, potentially providing a non-
antibiotic alternative intervention.
The origin of circulating miRNAs is unclear. RBCs contain 
miRNAs that they release upon hemolysis (39, 40). To exclude FigUre 6 | Continued
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artifacts from sample processing, we removed hemolytic samples 
and used plasma rather than serum, as the latter contains more 
Hb (and RBC miRNAs) due to coagulation damage (82, 83). 
Coagulopathy may drive pathophysiological levels of hemolysis 
and release of CIR-miRNAs, as seen for miR-486-5p and miR-
451a [abundant in RBCs (29)]. Although free Hb levels did not 
significantly increase with SIRS severity, levels of multiple CIR-
miRNAs inversely correlate with free Hb, indicating that these do 
not derive from RBCs in SIRS as in sepsis.
Our data suggest that CIR-miRNAs affected in SIRS may 
derive from inflammatory cells activated during disease. In par-
ticular, CIR-miRNAs may be released in the blood in association 
with inflammation-induced oxidative stress, as suggested by the 
positive correlation between Prdx-1 and multiple CIR-miRNAs. 
Prdx-1 is an anti-oxidant enzyme that mediates the elimination of 
H2O2 and can be secreted as a dimer by macrophages, upon TLR 
triggering (36, 37). Its expression is regulated mainly by the tran-
scription factor Nrf2, activated by ROS and various other reactive, 
electrophilic species (84). Its induction may be an indicator of a 
protective response to oxidative stress (85, 86). Because Prdx-1 is 
associated with immune cells activation (37), we asked whether 
SIRS-relevant CIR-miRNAs were derived from circulating 
immune cells upon activation. We found that miRNAs affected 
by SIRS severity were indeed increased >10-fold in supernatants 
of PBMC cultures after activation with bacterial SAg that drove 
~1.5-fold cell-expansion. Thus, sustained immune cell activation 
may explain the massive release of miRNAs regulated during 
severe SIRS. Macrophages/monocytes, T and NK cells could be 
possible candidates for the release of CIR-miRNAs.
Of note, activated PBMCs did not produce significant increase 
in the supernatant levels of miR-10b-5p, which was not affected by 
SIRS severity (Figure S3 in Supplementary Material). Unlike other 
miRNAs, the modest (<2-fold) increase of miR-122-5p upon SAg 
stimulation may be explained simply by cell proliferation, sug-
gesting that PBMCs contribute little to miR-122-5p blood levels. 
As hepatocytes highly express miR-122 and increased blood 
levels of miR-122 were previously associated with liver pathology 
(87), epithelial cell release of miR-122 and potentially other CIR-
miRNAs during SIRS should be further investigated in future.
In conclusion, our work opens up a number of questions 
about CIR-miRNAs for future investigation. Currently, the 
exact function of circulating miRNAs in inflammatory condi-
tions remains unknown. CIR-miRNAs released by cells in 
the body after inflammatory damage may act as DAMPs that 
bind to TLR ligands (33), a property that is shared by Prdx-1 
(86). For instance, small RNAs contained in exosomes can 
be phagocytosed in myeloid-origin, antigen-presenting like 
cells and trigger TLR7 signaling, in vitro (31). In this context, 
miRNAs may act as pro-inflammatory DAMPs to drive inflam-
matory cytokines (including IL-6) production downstream of 
intracellular TLRs (31). However, we previously found that 
pro-inflammatory cytokine levels inversely correlate with 
blood levels of CIR-miRNAs, suggesting that CIR-miRNAs may 
negatively regulate inflammation in vivo (35). In mice, regula-
tory T cells (Tregs) have been shown to dampen the activity of 
conventional T cells by miRNA transfer (88). Yet, it is unclear 
whether miRNAs from Tregs can exert suppression at distance. 
Furthermore, beyond targeting cytokine and inflammatory 
mediator expression, CIR-miRNAs may regulate inflamma-
tion also via indirect mechanisms, or a complex combination 
of direct and indirect mechanisms, by acting in concert on 
distinct targets, in multiple cell types, and in different organs. 
The dynamic contribution of immune cells to blood miRNAs 
has been frequently overlooked, despite inflammation clearly 
affecting them. Thus, while differences in miRNA transfer may 
exist in  vivo compared to in  vitro, future research is needed 
to clarify the role of CIR-miRNAs in immunopathological 
and homeostatic conditions. In particular, more research is 
needed to address which immune cells specifically produce 
CIR-miRNAs to be released in the blood, including when 
and how. Also the mode of trafficking and the cellular and 
molecular targets of CIR-miRNAs need to be identified yet. 
In future, such research may allow to harness CIR-miRNAs as 
immunomodulatory drugs useful for therapeutic purposes in 
inflammatory conditions as in other diseases.
eThics sTaTeMenT
Written informed consent or consultee approval to enroll was 
secured for all study participants (patients and healthy donors). 
This study was approved by the North Wales Research Ethics 
Committee (Central and East, reference 10/WNo03/19) and the 
BSMS Research Governance and Ethics Committee (reference: 
13/182/LLE) and carried out in accordance with the approved 
guidelines. All data were anonymized.
aUThOr cOnTriBUTiOns
SC and MM performed experiments and analyzed the data; SC, 
PG, SN, FK, and ML conceived and designed experiments; SC, 
SN, and ML wrote the first manuscript draft. All authors critically 
contributed to the final version of the manuscript.
acKnOWleDgMenTs
We thank staff and patients who participated in the clinical study. 
We thank Dr. Helen Stewart for reading the manuscript and other 
BSMS members at the University of Sussex for participating in 
useful discussions. We thank Dr. Antonio Sorrentino and Dr. 
Michael Thorsen (Exiqon), for assistance.
FUnDing
SC is supported by a Brighton and Sussex Medical School Internal 
Fellowship (University of Sussex). This work was funded by the 
University of Sussex Research Development Fund Round 3 (RDF 
3-021). The funders had no role in study design, data collection 
and analysis, decision to publish, or preparation of the manuscript.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/articles/10.3389/fimmu.2017.01977/
full#supplementary-material.
13
Caserta et al. Inflammatory-Relevant Blood miRNAs
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 8 | Article 1977
reFerences
1. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 
(1997) 84(7):920–35. doi:10.1002/bjs.1800840707 
2. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, 
et al. The third international consensus definitions for sepsis and septic shock 
(sepsis-3). JAMA (2016) 315(8):801–10. doi:10.1001/jama.2016.0287 
3. Brun-Buisson C. The epidemiology of the systemic inflammatory response. 
Intensive Care Med (2000) 26(Suppl 1):S64–74. doi:10.1007/s001340051121 
4. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. 
Use of the SOFA score to assess the incidence of organ dysfunction/failure 
in intensive care units: results of a multicenter, prospective study. Working 
group on “sepsis-related problems” of the European Society of Intensive Care 
Medicine. Crit Care Med (1998) 26(11):1793–800. doi:10.1097/00003246- 
199811000-00016 
5. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a sever-
ity of disease classification system. Crit Care Med (1985) 13(10):818–29. 
doi:10.1097/00003246-198510000-00009 
6. Matsuda N, Hattori Y. Systemic inflammatory response syndrome (SIRS): 
molecular pathophysiology and gene therapy. J Pharmacol Sci (2006) 
101(3):189–98. doi:10.1254/jphs.CRJ06010X 
7. Cohen J. The immunopathogenesis of sepsis. Nature (2002) 420(6917):885–91. 
doi:10.1038/nature01326 
8. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to 
systemic inflammatory response syndrome (SIRS)-like reactions through toll-
like receptor 4. J Immunol (2004) 172(1):20–4. doi:10.4049/jimmunol.172.1.20 
9. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. 
J Hepatobiliary Pancreat Surg (2002) 9(4):401–10. doi:10.1007/s005340200049 
10. Ulloa L, Tracey KJ. The “cytokine profile”: a code for sepsis. Trends Mol Med 
(2005) 11(2):56–63. doi:10.1016/j.molmed.2004.12.007 
11. Kietzmann D, Kahl R, Muller M, Burchardi H, Kettler D. Hydrogen peroxide 
in expired breath condensate of patients with acute respiratory failure and 
with ARDS. Intensive Care Med (1993) 19(2):78–81. doi:10.1007/BF01708366 
12. Quinlan GJ, Evans TW, Gutteridge JM. 4-hydroxy-2-nonenal levels 
increase in the plasma of patients with adult respiratory distress syn-
drome as linoleic acid appears to fall. Free Radic Res (1994) 21(2):95–106. 
doi:10.3109/10715769409056561 
13. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible 
nitric oxide synthase. J Leukoc Biol (1993) 54(2):171–8. 
14. Metnitz PG, Bartens C, Fischer M, Fridrich P, Steltzer H, Druml W. Antioxidant 
status in patients with acute respiratory distress syndrome. Intensive Care Med 
(1999) 25(2):180–5. doi:10.1007/s001340050813 
15. Gutteridge JM, Mitchell J. Redox imbalance in the critically ill. Br Med Bull 
(1999) 55(1):49–75. doi:10.1258/0007142991902295 
16. Swank DW, Moore SB. Roles of the neutrophil and other mediators in 
adult respiratory distress syndrome. Mayo Clin Proc (1989) 64(9):1118–32. 
doi:10.1016/S0025-6196(12)64981-7 
17. Botha AJ, Moore FA, Moore EE, Kim FJ, Banerjee A, Peterson VM. Postinjury 
neutrophil priming and activation: an early vulnerable window. Surgery 
(1995) 118(2):358–64; discussion 64–5. doi:10.1016/S0039-6060(05)80345-9 
18. Botha AJ, Moore FA, Moore EE, Sauaia A, Banerjee A, Peterson VM. Early neu-
trophil sequestration after injury: a pathogenic mechanism for multiple organ 
failure. J Trauma (1995) 39(3):411–7. doi:10.1097/00005373-199509000-00003 
19. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular 
coagulation is a frequent complication of systemic inflammatory response 
syndrome. Thromb Haemost (1996) 75(2):224–8. 
20. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, et  al. 
Natural cytokine antagonists and endogenous antiendotoxin core antibodies 
in sepsis syndrome. The sepsis intervention group. JAMA (1995) 274(2):172–7. 
doi:10.1001/jama.1995.03530020090038 
21. Ferguson KL, Taheri P, Rodriguez J, Tonapi V, Cardellio A, Dechert R. Tumor 
necrosis factor activity increases in the early response to trauma. Acad Emerg 
Med (1997) 4(11):1035–40. doi:10.1111/j.1553-2712.1997.tb03676.x 
22. Nast-Kolb D, Waydhas C, Gippner-Steppert C, Schneider I, Trupka A, 
Ruchholtz S, et  al. Indicators of the posttraumatic inflammatory response 
correlate with organ failure in patients with multiple injuries. J Trauma (1997) 
42(3):446–54; discussion 54–5. doi:10.1097/00005373-199703000-00012 
23. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA. Major injury induces 
increased production of interleukin-10 by cells of the immune system with 
a negative impact on resistance to infection. Ann Surg (1997) 226(4):450–8; 
discussion 8–60. doi:10.1097/00000658-199710000-00006 
24. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response 
syndrome (CARS) in critically ill patients. Clin Chest Med (2008) 29(4):617–25, 
viii. doi:10.1016/j.ccm.2008.06.010 
25. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
(2004) 116(2):281–97. doi:10.1016/S0092-8674(04)00045-5 
26. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 
(2009) 136(2):215–33. doi:10.1016/j.cell.2009.01.002 
27. Kroesen BJ, Teteloshvili N, Smigielska-Czepiel K, Brouwer E, Boots AM, 
van den Berg A, et al. Immuno-miRs: critical regulators of T-cell develop-
ment, function and ageing. Immunology (2015) 144(1):1–10. doi:10.1111/
imm.12367 
28. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, 
et  al. Argonaute2 complexes carry a population of circulating microRNAs 
independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 
108(12):5003–8. doi:10.1073/pnas.1019055108 
29. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing 
the MicroRNA spectrum between serum and plasma. PLoS One (2012) 
7(7):e41561. doi:10.1371/journal.pone.0041561 
30. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular 
miRNAs on circulating miRNA biomarker signatures. PLoS One (2011) 
6(6):e20769. doi:10.1371/journal.pone.0020769 
31. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et  al. 
MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory 
response. Proc Natl Acad Sci U S A (2012) 109(31):E2110–6. doi:10.1073/
pnas.1209414109 
32. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J, et al. 
An unconventional role for miRNA: let-7 activates toll-like receptor 7 and 
causes neurodegeneration. Nat Neurosci (2012) 15(6):827–35. doi:10.1038/
nn.3113 
33. Fabbri M. TLRs as miRNA receptors. Cancer Res (2012) 72(24):6333–7. 
doi:10.1158/0008-5472.CAN-12-3229 
34. Chen X, Liang H, Zhang J, Zen K, Zhang CY. MicroRNAs are ligands of toll-
like receptors. RNA (2013) 19(6):737–9. doi:10.1261/rna.036319.112 
35. Caserta S, Kern F, Cohen J, Drage S, Newbury SF, Llewelyn MJ. Circulating 
plasma microRNAs can differentiate human sepsis and systemic inflammatory 
response syndrome (SIRS). Sci Rep (2016) 6:28006. doi:10.1038/srep28006 
36. Checconi P, Salzano S, Bowler L, Mullen L, Mengozzi M, Hanschmann EM, 
et al. Redox proteomics of the inflammatory secretome identifies a common 
set of redoxins and other glutathionylated proteins released in inflammation, 
influenza virus infection and oxidative stress. PLoS One (2015) 10(5):e0127086. 
doi:10.1371/journal.pone.0127086 
37. Mullen L, Hanschmann EM, Lillig CH, Herzenberg LA, Ghezzi P. Cysteine 
oxidation targets peroxiredoxins 1 and 2 for exosomal release through a 
novel mechanism of redox-dependent secretion. Mol Med (2015) 21:98–108. 
doi:10.2119/molmed.2015.00033 
38. Llewelyn MJ, Berger M, Gregory M, Ramaiah R, Taylor AL, Curdt I, et  al. 
Sepsis biomarkers in unselected patients on admission to intensive or high-de-
pendency care. Crit Care (2013) 17(2):R60. doi:10.1186/cc12588 
39. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. 
Blood cell origin of circulating microRNAs: a cautionary note for cancer bio-
marker studies. Cancer Prev Res (Phila) (2012) 5(3):492–7. doi:10.1158/1940-
6207.CAPR-11-0370 
40. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk 
N, et al. Haemolysis during sample preparation alters microRNA content of 
plasma. PLoS One (2011) 6(9):e24145. doi:10.1371/journal.pone.0024145 
41. Harboe M. A method for determination of hemoglobin in plasma by 
near-ultraviolet spectrophotometry. Scand J Clin Lab Invest (1959) 11:66–70. 
doi:10.3109/00365515909060410 
42. Adamzik M, Hamburger T, Petrat F, Peters J, de Groot H, Hartmann M. Free 
hemoglobin concentration in severe sepsis: methods of measurement and 
prediction of outcome. Crit Care (2012) 16(4):R125. doi:10.1186/cc11425 
43. Han V, Serrano K, Devine DV. A comparative study of common techniques 
used to measure haemolysis in stored red cell concentrates. Vox Sang (2010) 
98(2):116–23. doi:10.1111/j.1423-0410.2009.01249.x 
44. Lippi G, Salvagno GL, Montagnana M, Brocco G, Guidi GC. Influence of 
hemolysis on routine clinical chemistry testing. Clin Chem Lab Med (2006) 
44(3):311–6. doi:10.1515/CCLM.2006.054 
14
Caserta et al. Inflammatory-Relevant Blood miRNAs
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 8 | Article 1977
45. Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Wrang Teilum M, 
et al. Assessing sample and miRNA profile quality in serum and plasma or 
other biofluids. Methods (2013) 59(1):S1–6. doi:10.1016/j.ymeth.2012.09.015 
46. Caserta S, Taylor AL, Terrazzini N, Llewelyn MJ. Induction of human 
regulatory T  cells with bacterial superantigens. Methods Mol Biol (2016) 
1396:181–206. doi:10.1007/978-1-4939-3344-0_16 
47. Taylor AL, Llewelyn MJ. Superantigen-induced proliferation of human 
CD4+CD25- T cells is followed by a switch to a functional regulatory phe-
notype. J Immunol (2010) 185(11):6591–8. doi:10.4049/jimmunol.1002416 
48. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative 
reverse transcription-PCR data: a model-based variance estimation approach 
to identify genes suited for normalization, applied to bladder and colon 
cancer data sets. Cancer Res (2004) 64(15):5245–50. doi:10.1158/0008-5472.
CAN-04-0496 
49. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. 
Hillsdale, NJ: L. Erlbaum Associates (1988). xxi, 567 p.
50. Taylor R. Interpretation of the correlation-coefficient – a basic review. J Diagn 
Med Sonog (1990) 6(1):35–9. doi:10.1177/875647939000600106 
51. Pearson K. On the criterion that a given system of deviations from the 
probable in the case of a correlated system of variables is such that it can be 
reasonably supposed to have arisen from random sampling. Philos Mag (1900) 
50(302):157–75. doi:10.1080/14786440009463897 
52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical 
and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 
(1995) 57(1):289–300. doi:10.2307/2346101 
53. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association 
with disease and potential use as biomarkers. Crit Rev Oncol Hematol (2011) 
80(2):193–208. doi:10.1016/j.critrevonc.2010.11.004 
54. Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as 
biomarkers in human diseases. Expert Rev Mol Diagn (2013) 13(2):183–204. 
doi:10.1586/erm.12.134 
55. Correia CN, Nalpas NC, McLoughlin KE, Browne JA, Gordon SV, MacHugh DE, 
et  al. Circulating microRNAs as potential biomarkers of infectious disease. 
Front Immunol (2017) 8:118. doi:10.3389/fimmu.2017.00118 
56. Brochner AC, Toft P. Pathophysiology of the systemic inflammatory response 
after major accidental trauma. Scand J Trauma Resusc Emerg Med (2009) 
17:43. doi:10.1186/1757-7241-17-43 
57. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med 
(1995) 21(Suppl 2):S258–63. doi:10.1007/BF01740764 
58. Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martinez JA, Marti A. 
Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J 
(2015) 29(9):3595–611. doi:10.1096/fj.14-260323 
59. Zeng Z, Gong H, Li Y, Jie K, Ding C, Shao Q, et al. Upregulation of miR-146a 
contributes to the suppression of inflammatory responses in LPS-induced 
acute lung injury. Exp Lung Res (2013) 39(7):275–82. doi:10.3109/01902148. 
2013.808285 
60. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, et al. MiR-150 
controls B cell differentiation by targeting the transcription factor c-Myb. Cell 
(2007) 131(1):146–59. doi:10.1016/j.cell.2007.07.021 
61. Benz F, Roy S, Trautwein C, Roderburg C, Luedde T. Circulating micro-
RNAs as biomarkers for sepsis. Int J Mol Sci (2016) 17(1):E78. doi:10.3390/
ijms17010078 
62. Xu T, Zhou Q, Che L, Das S, Wang L, Jiang J, et al. Circulating miR-21, miR-378, 
and miR-940 increase in response to an acute exhaustive exercise in chronic 
heart failure patients. Oncotarget (2016) 7(11):12414–25. doi:10.18632/
oncotarget.6966 
63. Jiang X, Xue M, Fu Z, Ji C, Guo X, Zhu L, et al. Insight into the effects of adipose 
tissue inflammation factors on miR-378 expression and the underlying mech-
anism. Cell Physiol Biochem (2014) 33(6):1778–88. doi:10.1159/000362957 
64. Gooch JL, King C, Francis CE, Garcia PS, Bai Y. Cyclosporine A alters expres-
sion of renal microRNAs: new insights into calcineurin inhibitor nephrotoxic-
ity. PLoS One (2017) 12(4):e0175242. doi:10.1371/journal.pone.0175242 
65. Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. 
Increased number of circulating exosomes and their microRNA cargos are 
potential novel biomarkers in alcoholic hepatitis. J Transl Med (2015) 13:261. 
doi:10.1186/s12967-015-0623-9 
66. Silakit R, Loilome W, Yongvanit P, Thongchot S, Sithithaworn P, Boonmars T, 
et al. Urinary microRNA-192 and microRNA-21 as potential indicators for 
liver fluke-associated cholangiocarcinoma risk group. Parasitol Int (2017) 
66(4):479–85. doi:10.1016/j.parint.2015.10.001 
67. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM, et al. 
MicroRNAs are differentially expressed in ulcerative colitis and alter expres-
sion of macrophage inflammatory peptide-2 alpha. Gastroenterology (2008) 
135(5):1624–35.e24. doi:10.1053/j.gastro.2008.07.068 
68. Ruckerl D, Jenkins SJ, Laqtom NN, Gallagher IJ, Sutherland TE, Duncan S, 
et al. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt sig-
naling as essential for IL-4-driven murine macrophage proliferation in vivo. 
Blood (2012) 120(11):2307–16. doi:10.1182/blood-2012-02-408252 
69. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 
in health and disease. RNA Biol (2011) 8(5):706–13. doi:10.4161/rna.8.5.16154 
70. Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, et al. An insertion/deletion polymor-
phism at miRNA-122-binding site in the interleukin-1alpha 3’ untranslated 
region confers risk for hepatocellular carcinoma. Carcinogenesis (2009) 
30(12):2064–9. doi:10.1093/carcin/bgp283 
71. Chu Q, Xu T. miR-192 targeting IL-1RI regulates the immune response in 
miiuy croaker after pathogen infection in  vitro and in  vivo. Fish Shellfish 
Immunol (2016) 54:537–43. doi:10.1016/j.fsi.2016.05.007 
72. Wan Q, Zhou Z, Ding S, He J. The miR-30a negatively regulates IL-17-
mediated signal transduction by targeting Traf3ip2. J Interferon Cytokine Res 
(2015) 35(11):917–23. doi:10.1089/jir.2014.0146 
73. Sun Y, Pan J, Mao S, Jin J. IL-17/miR-192/IL-17Rs regulatory feedback loop 
facilitates multiple myeloma progression. PLoS One (2014) 9(12):e114647. 
doi:10.1371/journal.pone.0114647 
74. Vasilescu C, Dragomir M, Tanase M, Giza D, Purnichescu-Purtan R, Chen M, 
et  al. Circulating miRNAs in sepsis-A network under attack: an in-silico 
prediction of the potential existence of miRNA sponges in sepsis. PLoS One 
(2017) 12(8):e0183334. doi:10.1371/journal.pone.0183334 
75. Xu Z, Ji J, Xu J, Li D, Shi G, Liu F, et al. MiR-30a increases MDSC differentiation 
and immunosuppressive function by targeting SOCS3 in mice with B-cell 
lymphoma. FEBS J (2017) 284(15):2410–24. doi:10.1111/febs.14133 
76. Liu W, Cao H, Ye C, Chang C, Lu M, Jing Y, et al. Hepatic miR-378 targets 
p110alpha and controls glucose and lipid homeostasis by modulating hepatic 
insulin signalling. Nat Commun (2014) 5:5684. doi:10.1038/ncomms6684 
77. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune 
cells. Annu Rev Immunol (2013) 31:675–704. doi:10.1146/annurev-immunol- 
032712-095946 
78. Wang X, Wang K, Han L, Zhang A, Shi Z, Zhang K, et al. PRDM1 is directly 
targeted by miR-30a-5p and modulates the Wnt/beta-catenin pathway 
in a Dkk1-dependent manner during glioma growth. Cancer Lett (2013) 
331(2):211–9. doi:10.1016/j.canlet.2013.01.005 
79. Wu J, Zheng C, Wang X, Yun S, Zhao Y, Liu L, et al. MicroRNA-30 family 
members regulate calcium/calcineurin signaling in podocytes. J Clin Invest 
(2015) 125(11):4091–106. doi:10.1172/JCI81061 
80. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et  al. 
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the 
p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer 
Cell (2010) 18(4):367–81. doi:10.1016/j.ccr.2010.09.005 
81. Ke S, Li RC, Lu J, Meng FK, Feng YK, Fang MH. MicroRNA-192 regulates 
cell proliferation and cell cycle transition in acute myeloid leukemia via 
interaction with CCNT2. Int J Hematol (2017) 106(2):258–65. doi:10.1007/
s12185-017-2232-2 
82. Fairbanks VF, Ziesmer SC, O’Brien PC. Methods for measuring plasma 
hemoglobin in micromolar concentration compared. Clin Chem (1992) 
38(1):132–40. 
83. Noe DA, Weedn V, Bell WR. Direct spectrophotometry of serum hemoglobin: 
an Allen correction compared with a three-wavelength polychromatic analy-
sis. Clin Chem (1984) 30(5):627–30. 
84. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer 
strategy. Nat Rev Drug Discov (2013) 12(12):931–47. doi:10.1038/nrd4002 
85. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. 
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence 
and tumour suppression. Nature (2003) 424(6948):561–5. doi:10.1038/
nature01819 
86. Knoops B, Argyropoulou V, Becker S, Ferte L, Kuznetsova O. Multiple roles of 
peroxiredoxins in inflammation. Mol Cells (2016) 39(1):60–4. doi:10.14348/
molcells.2016.2341 
15
Caserta et al. Inflammatory-Relevant Blood miRNAs
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 8 | Article 1977
87. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122 – a key factor and ther-
apeutic target in liver disease. J Hepatol (2015) 62(2):448–57. doi:10.1016/j.
jhep.2014.10.004 
88. Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, 
et  al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress 
pathogenic T helper 1 cells. Immunity (2014) 41(1):89–103. doi:10.1016/j.
immuni.2014.05.019 
Conflict of Interest Statement: The authors have no conflict of interest directly 
related to the current manuscript. However, SC, FK, SN, and ML are inventors 
in a patent submitted by the University of Sussex for the use of CIR-miRNAs as 
biomarkers of sepsis.
Copyright © 2018 Caserta, Mengozzi, Kern, Newbury, Ghezzi and Llewelyn. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) and the copyright owner are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
